Search research articles
Contact Us
Filters
Showing results (231-240 of 284) with videos related to
Page
of 29
Sort By:
European Journal of Cancer (Oxford, England : 1990)
|
February 8, 2023
Extensive molecular profiling of squamous cell anal carcinoma in a phase 2 trial population: Translational analyses of the "CARACAS" study
Alessandra A Prete, Paolo Manca, Marco Messina, et al.
JCO Precision Oncology
|
February 1, 2022
Atypical <i>RAS</i> Mutations in Metastatic Colorectal Cancer
Filippo Pietrantonio, Rona Yaeger, Alexa B Schrock, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research
|
March 26, 2021
The Landscape of Alterations in DNA Damage Response Pathways in Colorectal Cancer
Hiroyuki Arai, Andrew Elliott, Joanne Xiu, et al.
Nature Communications
|
January 12, 2026
Tucatinib plus trastuzumab for chemotherapy-refractory, HER2 + , RAS wild-type metastatic colorectal cancer (MOUNTAINEER): final analysis
John H Strickler, Andrea Cercek, Salvatore Siena, et al.
The Pharmacogenomics Journal
|
February 7, 2019
DPYD*6 plays an important role in fluoropyrimidine toxicity in addition to DPYD*2A and c.2846A>T: a comprehensive analysis in 1254 patients
Marzia Del Re, Saverio Cinieri, Angela Michelucci, et al.
European Journal of Cancer (Oxford, England : 1990)
|
December 15, 2020
Impact of early tumor shrinkage and depth of response on the outcomes of panitumumab-based maintenance in patients with RAS wild-type metastatic colorectal cancer
Paolo Manca, Salvatore Corallo, Giovanni Randon, et al.
Journal of the National Cancer Institute
|
April 7, 2021
EGFR Amplification in Metastatic Colorectal Cancer
Giovanni Randon, Rona Yaeger, Jaclyn F Hechtman, et al.
Clinical Colorectal Cancer
|
March 12, 2026
Consistency of Radiological Staging in Resectable Mismatch-Repair Proficient Colon Cancer: An Interobserver Agreement Study
Vincenzo Nasca, Gabriele Tinè, Marta Vaiani, et al.
ESMO Open
|
July 19, 2018
TRIPLETE: a randomised phase III study of modified FOLFOXIRI plus panitumumab versus mFOLFOX6 plus panitumumab as initial therapy for patients with unresectable <i>RAS</i> and <i>BRAF</i> wild-type metastatic colorectal cancer
Beatrice Borelli, Roberto Moretto, Sara Lonardi, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research
|
April 21, 2026
Molecular lineages of sporadic mismatch-repair deficient colorectal cancer
Michael B Foote, Guilherme Harada, Somer Abdelfattah, et al.
Page
of 29
Search research articles
Search
Showing results (231-240 of 284) with videos related to
Sort By:
Page
of 29
European Journal of Cancer (Oxford, England : 1990)
|
February 8, 2023
Extensive molecular profiling of squamous cell anal carcinoma in a phase 2 trial population: Translational analyses of the "CARACAS" study
Alessandra A Prete, Paolo Manca, Marco Messina, et al.
JCO Precision Oncology
|
February 1, 2022
Atypical <i>RAS</i> Mutations in Metastatic Colorectal Cancer
Filippo Pietrantonio, Rona Yaeger, Alexa B Schrock, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research
|
March 26, 2021
The Landscape of Alterations in DNA Damage Response Pathways in Colorectal Cancer
Hiroyuki Arai, Andrew Elliott, Joanne Xiu, et al.
Nature Communications
|
January 12, 2026
Tucatinib plus trastuzumab for chemotherapy-refractory, HER2 + , RAS wild-type metastatic colorectal cancer (MOUNTAINEER): final analysis
John H Strickler, Andrea Cercek, Salvatore Siena, et al.
The Pharmacogenomics Journal
|
February 7, 2019
DPYD*6 plays an important role in fluoropyrimidine toxicity in addition to DPYD*2A and c.2846A>T: a comprehensive analysis in 1254 patients
Marzia Del Re, Saverio Cinieri, Angela Michelucci, et al.
European Journal of Cancer (Oxford, England : 1990)
|
December 15, 2020
Impact of early tumor shrinkage and depth of response on the outcomes of panitumumab-based maintenance in patients with RAS wild-type metastatic colorectal cancer
Paolo Manca, Salvatore Corallo, Giovanni Randon, et al.
Journal of the National Cancer Institute
|
April 7, 2021
EGFR Amplification in Metastatic Colorectal Cancer
Giovanni Randon, Rona Yaeger, Jaclyn F Hechtman, et al.
Clinical Colorectal Cancer
|
March 12, 2026
Consistency of Radiological Staging in Resectable Mismatch-Repair Proficient Colon Cancer: An Interobserver Agreement Study
Vincenzo Nasca, Gabriele Tinè, Marta Vaiani, et al.
ESMO Open
|
July 19, 2018
TRIPLETE: a randomised phase III study of modified FOLFOXIRI plus panitumumab versus mFOLFOX6 plus panitumumab as initial therapy for patients with unresectable <i>RAS</i> and <i>BRAF</i> wild-type metastatic colorectal cancer
Beatrice Borelli, Roberto Moretto, Sara Lonardi, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research
|
April 21, 2026
Molecular lineages of sporadic mismatch-repair deficient colorectal cancer
Michael B Foote, Guilherme Harada, Somer Abdelfattah, et al.
Page
of 29